SLNO - Soleno Therapeutics Inc

SLNO - Soleno Therapeutics Inc

https://soleno.life

Buy Momentum: Bearish

Recent News

Powered by Alpha Vantage

Soleno Therapeutics ( SLNO ) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks Commentary • 4 days, 2 hours ago • score: 0.25

Soleno Therapeutics (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the ...

Unpacking the Latest Options Trading Trends in Soleno Therapeutics - Soleno Therapeutics ( NASDAQ:SLNO )

Benzinga • 4 days, 21 hours ago • score: 0.24

Deep-pocketed investors have adopted a bearish approach towards Soleno Therapeutics SLNO, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.

SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )

Benzinga • 6 days, 18 hours ago • score: -0.20

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options

SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. ( NASDAQ: SLNO ) , You Are Encouraged to Contact The Rosen Law Firm About Your Rights - Soleno Therapeutics ( NASDAQ:SLNO )

Benzinga • 1 week, 1 day ago • score: -0.18

NEW YORK, Sept. 07, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc.

Soleno Therapeutics to Participate in Upcoming September Conferences

GlobeNewswire • 2 weeks, 5 days ago • score: 0.20

REDWOOD CITY, Calif., Aug. 27, 2025 ( GLOBE NEWSWIRE ) -- Soleno Therapeutics, Inc. ( "Soleno" ) ( NASDAQ: SLNO ) , a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in ...

SOLENO ALERT: Bragar Eagel & Squire, P.C. is Investigating Soleno Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm - Soleno Therapeutics ( NASDAQ:SLNO )

Benzinga • 2 weeks, 5 days ago • score: -0.20

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Soleno ( SLNO ) To Contact Him Directly To Discuss Their Options

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company is headquartered in Redwood City, California.

52W High

$90.32

52W Low

$41.50

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

-2.72

Valuation

Rich

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

29.07

EV/EBITDA (<8 favorable)

0.02

EV/Revenue (<3 favorable)

106.37

P/S (TTM) (<3 favorable)

113.54

P/B (<3 favorable)

15.44

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

1.79%

Institutions (25–75% balanced)

110.12%

Shares Outstanding

53,145,000

Float

44,870,900

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

32,657,000

Gross Profit (TTM)

31,961,000

EPS (TTM)

-4.22

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-0.17%

ROE (TTM) (>15% strong)

-0.70%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

-3.9072

Previous

-4.3093

Trend

Rising

Signal Cross

No cross

As of

Sep. 05, 2025